Wuhan Hiteck Biological Pharma Co Ltd
SZSE:300683

Watchlist Manager
Wuhan Hiteck Biological Pharma Co Ltd Logo
Wuhan Hiteck Biological Pharma Co Ltd
SZSE:300683
Watchlist
Price: 33.31 CNY 7.66% Market Closed
Market Cap: ¥4.4B

Wall Street
Price Targets

Price Targets Summary
Wuhan Hiteck Biological Pharma Co Ltd

There are no price targets for Wuhan Hiteck Biological Pharma Co Ltd.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Wuhan Hiteck Biological Pharma Co Ltd Competitors:
Price Targets
MRVL
Marvell Technology Group Ltd
47% Upside
8841
TOC Co Ltd
23% Upside
IBEX
Ibex Ltd
8% Upside
CASY
Caseys General Stores Inc
0% Downside

Revenue
Forecast

-1% / Year
Past Growth
-24% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
-1% / Year
Past Growth
-24% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

For the last 9 years the compound annual growth rate for Wuhan Hiteck Biological Pharma Co Ltd's revenue is -1%. The projected CAGR for the next 5 years is -24%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Operating Income forecast
is not available for
Wuhan Hiteck Biological Pharma Co Ltd

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Net Income forecast
is not available for
Wuhan Hiteck Biological Pharma Co Ltd
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Wuhan Hiteck Biological Pharma Co Ltd's stock price target?
Not Available

Wuhan Hiteck Biological Pharma Co Ltd doesn't have any price targets made by Wall Street professionals.

What is Wuhan Hiteck Biological Pharma Co Ltd's Revenue forecast?
Projected CAGR
-24%

For the last 9 years the compound annual growth rate for Wuhan Hiteck Biological Pharma Co Ltd's revenue is -1%. The projected CAGR for the next 5 years is -24%.

Back to Top